NCT06303830

Brief Summary

Inorganic nitrite and nitrate can be reduced to NO and NO-related species such as S-nitrosothiols via the nitrate-nitrite-NO pathway. This is due to the reduction of nitrate to nitrite by the action of bacteria in the mouth and the reduction of nitrite to NO depending on the acidic pH on the stomach or by enzymes with nitrite-reductase activity. The acidic environment of the stomach is very important to the formation of NO and S-nitrosothiols and several studies suggest that changes in gastric pH can affect this conversion. In this context, bariatric surgery, by altering the anatomy of the stomach and increasing gastric pH, can affect the nitrate-nitrite-NO pathway and change the antihypertensive and antioxidant effect of sodium nitrate.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable hypertension

Timeline
Completed

Started Apr 2019

Typical duration for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 16, 2019

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 17, 2020

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2021

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

March 4, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 12, 2024

Completed
Last Updated

March 12, 2024

Status Verified

March 1, 2024

Enrollment Period

1.7 years

First QC Date

March 4, 2024

Last Update Submit

March 4, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Assess changes in s-nitrosothiols

    Change in s-nitrosothiols concentration in plasma After Sodium Nitrate Treatment

    14 days

Secondary Outcomes (5)

  • Assess changes in blood pressure

    14 days

  • Assess changes in endotelial function

    14 days

  • Assess changes in Vascular stiffness

    14 days

  • Assess changes in nitrate concentration

    14 days

  • Assess changes in nitrite concentration

    14 days

Study Arms (2)

Control group

ACTIVE COMPARATOR

Sodium nitrate, once a day for 14 days

Dietary Supplement: Sodium nitrate

Bariatric group

EXPERIMENTAL

Sodium nitrate, once a day for 14 days

Dietary Supplement: Sodium nitrate

Interventions

Sodium nitrateDIETARY_SUPPLEMENT

Sodium Nitrate

Bariatric groupControl group

Eligibility Criteria

Age18 Years - 60 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • For volunteers who underwent bariatric surgery:
  • Female;
  • Age over 18 years old and under 60 years old;
  • Having had bariatric surgery more than 1 and a half years ago;
  • Present stabilized weight loss;
  • For voluntary controls:
  • Female;
  • Age over 18 years old and under 60 years old;

You may not qualify if:

  • For volunteers who underwent bariatric surgery and controls:
  • Having uncontrolled blood pressure (above 160/100 mmHg), even with use regulate up to two antihypertensive agents;
  • Hypertensive patients must be using a maximum of two antihypertensives;
  • Have Diabetes Mellitus or other endocrinopathy;
  • Have kidney or liver failure;
  • Individuals who smoke.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Usp - Hospital Das Clínicas Da Faculdade de Medicina de Ribeirão

Ribeirão Preto, São Paulo, 14.048-900, Brazil

Location

MeSH Terms

Conditions

Hypertension

Interventions

sodium nitrate

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD in Pharmacology

Study Record Dates

First Submitted

March 4, 2024

First Posted

March 12, 2024

Study Start

April 16, 2019

Primary Completion

December 17, 2020

Study Completion

October 1, 2021

Last Updated

March 12, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations